Genes & biomarkers
KRAS variants
KRAS · G12C / G12D / G12V
The exact variant, such as G12C, matters more than “KRAS positive” alone.
Sources checked · Introductory guide
On this page
What does this result mean?
KRAS acts as a switch for cell growth signals. Some variants keep the signal active and occur in cancers including lung and colorectal cancer.[1]
How does it connect to treatment?
In the US, sotorasib plus panitumumab is approved for KRAS G12C metastatic colorectal cancer after specified chemotherapy. This evidence cannot simply be applied to G12D, G12V or other variants.[2]
What should I check in my report?
Check the exact variant, cancer type and prior treatment requirements. Even the same variant may require different combinations and treatment sequences in lung and colorectal cancer.
Questions for your care team
- Is my result G12C or another KRAS variant?
- Which treatments or trials fit my cancer type, stage and previous treatment?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- MedlinePlus Genetics · KRAS (opens in a new tab)
- FDA · Sotorasib with panitumumab for KRAS G12C colorectal cancer (opens in a new tab)
- NCI · Sotorasib (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.